Lupin Limited inaugurated Atharv Ability, its advanced multidisciplinary neuro-rehabilitation center in Naraina Vihar, Delhi, on May 15, 2026. The facility is dedicated to delivering comprehensive, outcome-driven, specialized care for adults and children with neurological disabilities, with a focus on enhancing mobility, improving quality of life, and supporting long-term recovery. The launch was disclosed pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Expanding Access to Specialized Neuro-Rehabilitation in North India

The Delhi center represents the third Atharv Ability facility under Lupin's neuro-rehabilitation initiative, following the successful launch of centers in Mumbai in 2023 and Hyderabad in 2024. The expansion targets a region where access to integrated, high-quality neuro-rehabilitation services remains limited, aiming to bridge critical treatment gaps for patients across North India.

The center addresses a wide spectrum of neurological conditions, including:

• Stroke
• Traumatic brain injury
• Spinal cord injury
• Parkinson's disease
• Multiple sclerosis
• Pediatric neurological disorders such as cerebral palsy

Advanced Technology and Multidisciplinary Care

Atharv Ability integrates clinical expertise with cutting-edge technology to deliver personalized care programs. The key features of the Delhi facility are outlined below:

Leadership Commentary

Commenting on the launch, Rajeev Sibal, President – India Region Formulations, Lupin, said, "As advances in neurological treatment continue to improve outcomes, rehabilitation offers a powerful opportunity to restore independence and enable meaningful recovery. Atharv Ability embodies this belief that healthcare must extend beyond treatment to sustained recovery, with personalized, patient-focused care. This expansion underscores our belief that high-quality neuro-rehabilitation must be accessible, affordable, and standardized across India."

About Lupin Limited

Lupin Limited is a global pharmaceutical company headquartered in Mumbai, India, with products distributed in over 100 markets. The company specializes in branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Lupin maintains a strong presence in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. The company operates 15 state-of-the-art manufacturing sites and 7 research centers globally, supported by a workforce of over 24,000 professionals. Lupin's subsidiaries — Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions — further its commitment to improving patient health outcomes.

Lupin has received a tentative approval from the United States Food and Drug Administration (US FDA) for Refevenacin Inhalation Solution. This regulatory development represents a notable milestone for the company as it continues to strengthen its portfolio in the US pharmaceutical market.

Regulatory Approval Details

The tentative approval from the US FDA signifies that Refevenacin Inhalation Solution has satisfied the regulatory agency's requirements for safety, efficacy, and quality. A tentative approval is granted when a drug product meets all required criteria but is not yet eligible for final approval due to existing patents or exclusivity periods.

Significance of the Development

This tentative approval underscores Lupin's continued focus on expanding its respiratory product offerings in the United States. Refevenacin Inhalation Solution is a bronchodilator used in the management of chronic obstructive pulmonary disease (COPD), a significant therapeutic area in the US market. The approval reflects the company's ongoing efforts to build a robust pipeline of specialty and generic pharmaceutical products for the US market.